A Novel Technique Using Lyophilized Amniotic Membrane Patch (LAMPatch) as Primary Procedure in Patients with Myopic Traction Maculopathy with Macular Detachment

Abel Ramirez-Estudillo,1,2 Sergio Rojas-Juarez,2 Ximena Ramirez-Galicia,1 Angel Garcia-Vasquez,2 Silvia Medina-Medina,2 Rosario Gulias-Cañizo1,3 1Centro Oftalmológico Mira, Mexico City, Mexico; 2Retina Department, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico; 3Centro de Investigación en Ciencias de la Salud, Universidad Anahuac, Estado de Mexico, MexicoCorrespondence: Abel Ramirez-Estudillo, Rosario Gulias-Cañizo, Centro Oftalmológico Mira, Taxco 35, Col. Roma Sur, C.P. 06760, Mexico City, Mexico, Email [email protected]; [email protected]: Maculopathy secondary to pathologic myopia (PM) is increasingly causing visual impairment and blindness worldwide. PM is associated with tractional maculopathy that ranges from macular foveoschisis to macular hole. These disorders are treated with different options that offer variable results, reflecting the need for new techniques that address myopic maculopathy with consistent outcomes.Methods: Since human amniotic membrane (HAM) has been reported to be safe for intraocular use and to promote retinal healing, it was incorporated as an adjuvant in pars plana vitrectomy in patients with different tractional disorders related to myopia. This work presents a prospective, consecutive case series of seven patients with high myopia who underwent a 25-gauge vitrectomy with ILM peeling and HAM transplantation.Results and Discussion: Our six-month results show that this novel technique delivers functional success related to tissue permanence without recurrence of traction that translates into visual acuity gain and maintenance that are superior to other techniques.Keywords: retinal surgery, macular surgery, lyophilized amniotic membrane, amniotic membrane patch, LAMPatch, myopic traction maculopathy, macular hole, retinal detachment